세계의 유전성 암 검사 시장 리포트(2023년)

“Hereditary Cancer Testing Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hereditary cancer testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hereditary cancer testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The hereditary cancer testing market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Test Type: Multi Panel Test; Single-site Genetic Test

• 2) By Indication: Breast Cancer; Ovarian Cancer; Colorectal Cancer; Other Indications

• 3) By End user: Hospital; Clinics; Diagnostic Centers

• Companies Mentioned: Centogene NV; Ambry Genetics; Myriad Genetics Inc.; NeoGenomics Laboratories Inc.; Quest Diagnostics

• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

• Time series: Five years historic and ten years forecast.

• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the hereditary cancer testing market are: Centogene NV, Ambry Genetics, Myriad Genetics Inc., NeoGenomics Laboratories Inc., Quest Diagnostics, PreventionGenetics, Fulgent Genetics, Invitae Corporation, Medical Diagnostic Laboratories LLC, Natera Inc., Color Health, CooperSurgica Inc., OPKO Health Inc., Illumina Inc., Laboratory Corporation of America Holdings, Pathway Genomics Corporation, Strand Life Sciences Private Limited, Progenity Inc., Myogenes, Counsyl, and ARUP Laboratories.

The global hereditary cancer testing market is expected to grow from $3.55 billion in 2022 to $3.95 billion in 2023 at a compound annual growth rate (CAGR) of 11.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The hereditary cancer testing market is expected to grow to $5.82 billion in 2027 at a CAGR of 10.2%.

The hereditary cancer testing market includes revenues earned by entities by providing hereditary cancer testing for lung cancer, cervical cancer, prostate cancer, stomach/gastric cancer, melanoma, sarcoma, and uterine cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The hereditary cancer testing refer to testing methods for hereditary cancers which can identify specific hereditary cancer diseases and disease-related gene mutations. This testing may decrease the risk of developing particular cancer mutants allowing for comprehensive cancer risk for patients. The primary purpose of this cancer testing is to detect hereditary cancer early and maximize patient health outcomes. This testing procedure assists in identifying cancers that one has a genetic risk and allows them to receive preventive treatment.

North America was the largest region in the hereditary cancer testing market in 2022. The regions covered in the hereditary cancer testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main types of tests of hereditary cancer testing are multi panel test and single-site genetic test. The multi panel test refers to hereditary cancer test that is used to detect many chemicals simultaneously. Panels come in a variety of types, from three-panel tests that look for three substances to five, seven, to 12-panel tests. The choice of conducting required number of tests is up to a tester's discretion. The hereditary cancer testing is conducted for detecting breast cancer, ovarian cancer, colorectal cancer, and other indications that are used in hospitals, clinics, and diagnostic centers.

The increasing prevalence of hereditary cancer is expected to drive the hereditary cancer testing market. Mutations in specific genes passed down from parents to children cause hereditary cancer syndromes. Hereditary cancer testing can detect specific, heritable, disease-related gene mutations, allowing for a comprehensive cancer risk assessment for patients. For instance, in June 2022, according to an article published on BioMed Central about hereditary cancer in clinical practice states that about 10% of pancreatic cancer cases have a genetic background. Furthermore, in May 2021, a Europe-based SOPHiA genetics, a data-driven medicine software company, stated in an article that hereditary accounts for approximately 10% of cancer cases, with an estimated 20% of cancer patients having cancer family history. Therefore, the increasing prevalence of hereditary cancer drives the growth of the hereditary cancer testing market.

Technological innovation is a key trend gaining popularity in the hereditary cancer testing market. Key players in the market are focusing on technological innovations to sustain their market position. For instance, in March 2022, Myriad Genetics, US-based genetic testing and precision medicine company, launched genetic testing with Polygenic Breast Cancer Risk Assessment Score for all ancestries. This MyRisk Hereditary Cancer test with RiskScore offers a personalized breast cancer risk assessment to all women who have never been diagnosed with breast cancer, regardless of ancestry.

In January 2020, Quest Diagnostics, a US-based clinical laboratory company, acquired Blueprint Genetics for an undisclosed amount. With this acquisition Quest and Blueprint Genetics will improve patient care and pharmaceutical medication research and development by increasing access to practical insights into genetic and rare diseases. Blueprint Genetics is a US-based company offering complete genetic testing and genetic diagnostics to medical professionals.

The countries covered in the hereditary cancer testing market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The hereditary cancer testing market research report is one of a series of new reports from The Business Research Company that provides hereditary cancer testing market statistics, including hereditary cancer testing industry global market size, regional shares, competitors with a hereditary cancer testing market share, detailed hereditary cancer testing market segments, market trends and opportunities, and any further data you may need to thrive in the hereditary cancer testing industry. This hereditary cancer testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Table of Contents

1. Executive Summary

2. Hereditary Cancer Testing Market Characteristics

3. Hereditary Cancer Testing Market Trends And Strategies

4. Hereditary Cancer Testing Market - Macro Economic Scenario

• 4.1. COVID-19 Impact On Hereditary Cancer Testing Market
• 4.2. Ukraine-Russia War Impact On Hereditary Cancer Testing Market
• 4.3. Impact Of High Inflation On Hereditary Cancer Testing Market

5. Hereditary Cancer Testing Market Size And Growth

• 5.1. Global Hereditary Cancer Testing Historic Market, 2017-2022, $ Billion
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints On The Market
• 5.2. Global Hereditary Cancer Testing Forecast Market, 2022-2027F, 2032F, $ Billion
  • 5.2.1. Drivers Of The Market
  • 5.2.2. Restraints On the Market

6. Hereditary Cancer Testing Market Segmentation

• 6.1. Global Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Multi Panel Test
• Single-Site Genetic Test
• 6.2. Global Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Breast Cancer
• Ovarian Cancer
• Colorectal Cancer
• Other Indications
• 6.3. Global Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Hospital
• Clinics
• Diagnostic Centers

7. Hereditary Cancer Testing Market Regional And Country Analysis

• 7.1. Global Hereditary Cancer Testing Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 7.2. Global Hereditary Cancer Testing Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Hereditary Cancer Testing Market

• 8.1. Asia-Pacific Hereditary Cancer Testing Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 8.3. Asia-Pacific Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Hereditary Cancer Testing Market

• 9.1. China Hereditary Cancer Testing Market Overview
• 9.2. China Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
• 9.3. China Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Hereditary Cancer Testing Market

• 10.1. India Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 10.2. India Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Hereditary Cancer Testing Market

• 11.1. Japan Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 11.2. Japan Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Hereditary Cancer Testing Market

• 12.1. Australia Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 12.2. Australia Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Hereditary Cancer Testing Market

• 13.1. Indonesia Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 13.2. Indonesia Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Hereditary Cancer Testing Market

• 14.1. South Korea Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 14.2. South Korea Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Hereditary Cancer Testing Market

• 15.1. Western Europe Hereditary Cancer Testing Market Overview
• 15.2. Western Europe Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 15.3. Western Europe Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Hereditary Cancer Testing Market

• 16.1. UK Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 16.2. UK Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Hereditary Cancer Testing Market

• 17.1. Germany Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 17.2. Germany Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Hereditary Cancer Testing Market

• 18.1. France Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 18.2. France Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe Hereditary Cancer Testing Market

• 19.1. Eastern Europe Hereditary Cancer Testing Market Overview
• 19.2. Eastern Europe Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 19.3. Eastern Europe Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia Hereditary Cancer Testing Market

• 20.1. Russia Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 20.2. Russia Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America Hereditary Cancer Testing Market

• 21.1. North America Hereditary Cancer Testing Market Overview
• 21.2. North America Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 21.3. North America Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA Hereditary Cancer Testing Market

• 22.1. USA Hereditary Cancer Testing Market Overview
• 22.2. USA Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 22.3. USA Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America Hereditary Cancer Testing Market

• 23.1. South America Hereditary Cancer Testing Market Overview
• 23.2. South America Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 23.3. South America Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil Hereditary Cancer Testing Market

• 24.1. Brazil Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 24.2. Brazil Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East Hereditary Cancer Testing Market

• 25.1. Middle East Hereditary Cancer Testing Market Overview
• 25.2. Middle East Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 25.3. Middle East Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa Hereditary Cancer Testing Market

• 26.1. Africa Hereditary Cancer Testing Market Overview
• 26.2. Africa Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 26.3. Africa Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Hereditary Cancer Testing Market Competitive Landscape And Company Profiles

• 27.1. Hereditary Cancer Testing Market Competitive Landscape
• 27.2. Hereditary Cancer Testing Market Company Profiles
  • 27.2.1. Centogene NV
    • 27.2.1.1. Overview
    • 27.2.1.2. Products and Services
    • 27.2.1.3. Strategy
    • 27.2.1.4. Financial Performance
  • 27.2.2. Ambry Genetics
    • 27.2.2.1. Overview
    • 27.2.2.2. Products and Services
    • 27.2.2.3. Strategy
    • 27.2.2.4. Financial Performance
  • 27.2.3. Myriad Genetics Inc
    • 27.2.3.1. Overview
    • 27.2.3.2. Products and Services
    • 27.2.3.3. Strategy
    • 27.2.3.4. Financial Performance
  • 27.2.4. NeoGenomics Laboratories Inc
    • 27.2.4.1. Overview
    • 27.2.4.2. Products and Services
    • 27.2.4.3. Strategy
    • 27.2.4.4. Financial Performance
  • 27.2.5. Quest Diagnostics
    • 27.2.5.1. Overview
    • 27.2.5.2. Products and Services
    • 27.2.5.3. Strategy
    • 27.2.5.4. Financial Performance

28. Key Mergers And Acquisitions In The Hereditary Cancer Testing Market

29. Hereditary Cancer Testing Market Future Outlook and Potential Analysis

30. Appendix

• 30.1. Abbreviations
• 30.2. Currencies
• 30.3. Historic And Forecast Inflation Rates
• 30.4. Research Inquiries
• 30.5. The Business Research Company
• 30.6. Copyright And Disclaimer